Elanco Animal Health Incorporated (NYSE:ELAN) Sees Large Drop in Short Interest

Elanco Animal Health Incorporated (NYSE:ELAN) saw a significant decrease in short interest in the month of February. As of February 27th, there was short interest totaling 15,072,733 shares, a decrease of 18.1% from the February 12th total of 18,414,142 shares. Approximately 3.1% of the company’s stock are sold short. Based on an average daily volume of 5,231,386 shares, the short-interest ratio is currently 2.9 days. Based on an average daily volume of 5,231,386 shares, the short-interest ratio is currently 2.9 days. Approximately 3.1% of the company’s stock are sold short.

Institutional Trading of Elanco Animal Health

A number of institutional investors and hedge funds have recently bought and sold shares of ELAN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Elanco Animal Health in the first quarter worth about $2,065,000. Goldman Sachs Group Inc. lifted its stake in shares of Elanco Animal Health by 104.5% in the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after buying an additional 2,445,872 shares in the last quarter. Empowered Funds LLC grew its holdings in shares of Elanco Animal Health by 35.2% during the first quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock valued at $166,000 after buying an additional 4,121 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Elanco Animal Health by 4.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock valued at $18,830,000 after buying an additional 76,408 shares during the last quarter. Finally, ProShare Advisors LLC increased its position in shares of Elanco Animal Health by 8.7% during the second quarter. ProShare Advisors LLC now owns 12,439 shares of the company’s stock valued at $178,000 after acquiring an additional 999 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Stock Up 2.0%

NYSE:ELAN traded up $0.46 during trading hours on Monday, reaching $23.40. 3,818,611 shares of the company traded hands, compared to its average volume of 4,137,086. The company has a current ratio of 2.17, a quick ratio of 1.08 and a debt-to-equity ratio of 0.60. The business’s 50-day moving average price is $24.53 and its two-hundred day moving average price is $22.28. Elanco Animal Health has a 1 year low of $8.02 and a 1 year high of $27.72. The stock has a market capitalization of $11.64 billion, a P/E ratio of -48.76, a P/E/G ratio of 2.92 and a beta of 1.83.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The firm had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the prior year, the firm posted $0.14 earnings per share. The company’s quarterly revenue was up 12.2% on a year-over-year basis. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Analysts predict that Elanco Animal Health will post 0.91 earnings per share for the current year.

Analysts Set New Price Targets

ELAN has been the subject of several recent research reports. Leerink Partners raised their price objective on Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Tuesday, February 24th. JPMorgan Chase & Co. upped their target price on shares of Elanco Animal Health from $24.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, February 19th. Morgan Stanley increased their price target on shares of Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 25th. KeyCorp boosted their price objective on shares of Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Finally, Piper Sandler upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $24.00 to $30.00 in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.67.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.